Tandem Diabetes Care - TNDM Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings or view top-rated stocks.

7 equities research analysts have issued 1-year price targets for Tandem Diabetes Care's shares. Their TNDM share price forecasts range from $49.00 to $150.00. On average, they anticipate the company's stock price to reach $103.36 in the next year. This suggests a possible upside of 104.3% from the stock's current price.
View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts.

Tandem Diabetes Care's stock was trading at $150.52 on January 1st, 2022. Since then, TNDM shares have decreased by 66.4% and is now trading at $50.59.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TNDM earnings forecast.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) announced its quarterly earnings results on Wednesday, August, 3rd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by $0.27. The medical device company earned $200.26 million during the quarter, compared to analyst estimates of $205.16 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 2.99% and a negative net margin of 1.72%.

Tandem Diabetes Care shares reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $835.00 million-$845.00 million, compared to the consensus revenue estimate of $857.12 million.

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TNDM stock can currently be purchased for approximately $50.59.

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $3.25 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($0.22) on an earnings per share basis.

The company employs 2,000 workers across the globe.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.